Long-term immunoprophylaxis by TLR9 ligand mediates macrophage-ILC cross-talk against respiratory viral infection
Authors:
- Asuka Joy TobuseATAsuka Joy Tobuse
- Kouji KobiyamaKKKouji Kobiyama
- Daichi UtsumiDUDaichi Utsumi
- Mariana Silva AlmeidaMAMariana Silva Almeida
- Yaeko Nakajima-TakagiYNYaeko Nakajima-Takagi
- Motohiko OshimaMOMotohiko Oshima
- Tomoya HayashiTHTomoya Hayashi
- Burcu TemizozBTBurcu Temizoz
- Etsushi KurodaEKEtsushi Kuroda
- Cevayir CobanCCCevayir Coban
- 9 October 2026
- journal article
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (41)
Abstract
Rapid development of host immunity is critical during the emergence of viral outbreaks when vaccines are not yet available. Here, we demonstrate that CpG oligodeoxynucleotide-schizophyllan complex (K3-SPG) induces antigen-independent, long-term protection against lethal respiratory virus infection. A single intranasal administration successfully enhanced host resistance to infection for as long as 100 days posttreatment. Mechanistically, we observed a lung-restricted biphasic innate activation of macrophages and innate lymphoid cells. Early protection was mediated by CD11b + CD11c + macrophages (DP MΦ) and monocyte-derived interstitial macrophages (IMΦ). Late protection was mediated by innate lymphoid cells that were epigenetically reprogrammed, suggesting that two distinct innate immune subsets contribute to the maintenance of disease tolerance in the lung microenvironment. Deficiency of TLR9 or TNF-α abrogated innate activation and protective immunity. Collectively, these findings demonstrate that adjuvant-induced prophylaxis is a promising approach to enhancing host resistance against respiratory virus infection, involving the biphasic cooperation between innate immune cells in the local tissue.Keywords
Funding Information
- Japan Agency for Medical Research and Development (JP223fa727002)
- Japan Agency for Medical Research and Development (JP223fa727001)
- Japan Agency for Medical Research and Development (JP223fa627001)
- Japan Agency for Medical Research and Development (JP223fa627007)
- Japan Agency for Medical Research and Development (JP223fa627005)
- Japan Agency for Medical Research and Development (21ak0101162)
- Japan Agency for Medical Research and Development (JP223fa727001)
- Japan Agency for Medical Research and Development (JP25m2110005)
This publication has 72 references indexed in Scilit:
- Near-infrared photoimmunotherapy as a complementary modality to in situ vaccine in a preclinical pancreatic cancer modelBiochemical and Biophysical Research Communications, 2024
- ILC precursors differentiate into metabolically distinct ILC1-like cells during Mycobacterium tuberculosis infectionCell Reports, 2022
- β-Glucan Induces Protective Trained Immunity against Mycobacterium tuberculosis Infection: A Key Role for IL-1Cell Reports, 2020
- Immuno-Oncology beyond TILs: Unleashing TILCsCancer Cell, 2020
- ILC1 Confer Early Host Protection at Initial Sites of Viral InfectionCell, 2017
- Inhaled Fine Particles Induce Alveolar Macrophage Death and Interleukin-1α Release to Promote Inducible Bronchus-Associated Lymphoid Tissue FormationImmunity, 2016
- Trained Immunity: A Memory for Innate Host DefenseCell Host & Microbe, 2011
- Toll‐like receptor 9 binds single‐stranded CpG‐DNA in a sequence‐ and pH‐dependent mannerEuropean Journal of Immunology, 2004
- RAG-2-deficient mice lack mature lymphocytes owing to inability to initiate V(D)J rearrangementCell, 1992
- Clinical evaluation of schizophyllan combined with irradiation in patients with cervical cancer: A randomized controlled studyCancer, 1986